TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04938284

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PAS
Description: Paired associative stimulation is a combination of non-invasive transcranial magnetic stimulation (TMS) and non-invasive peripheral nerve stimulation (PNS)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PAS
Description: Paired associative stimulation is a combination of non-invasive transcranial magnetic stimulation (TMS) and non-invasive peripheral nerve stimulation (PNS)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PAS
Description: Paired associative stimulation is a combination of non-invasive transcranial magnetic stimulation (TMS) and non-invasive peripheral nerve stimulation (PNS)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VNS
Description: Non-invasive vagus nerve stimulation delivered through cymba concha \& cymba cavum of the ear.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VNS
Description: Non-invasive vagus nerve stimulation delivered through cymba concha \& cymba cavum of the ear.
Study: NCT05934721

Intervention type: OTHER
Intervention: Questionnaire and physical assessments
Description: Participants will complete self-report questionnaires assessing pain (CSI) and RA severity (patient global VAS), as well as undergoing physical assessments of RA severity (physician global VAS, swollen/tender joint counts) and cognition (MoCA).
Study: NCT06404892

Intervention type: PROCEDURE
Intervention: Single-lung ventilation
Description: Patients undergoing thoracic surgery and intraoperative single-lung ventilation.
Study: NCT04810403

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SOMEBODY Eating Disorder Prevention Program
Description: Participants will receive daily activities to complete on their most frequently used social media platform for 14 consecutive days. Daily activities have been adapted from the Body Project - an intervention that has been demonstrated to reduce internalization of the thin ideal and reduce risk for eating disorders. Examples of activities to be piloted include unfollowing social media accounts the participant perceives as reinforcing the thin-ideal and posting a selfie without makeup or editing. Based on feedback from participants, the intervention may be altered to improve acceptability, feasibility, and preliminary evidence of potential efficacy.
Study: NCT06093945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR2554 tablet dosing
Description: SHR2554 350mg taken on Day 1 and Day 10

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole tablet dosing
Description: Omeprazole taken from Days 5 to Day 10
Study: NCT05103475

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rage Against the Pain (RAP)
Description: The sets of body positions used in the RAP program will mirror those used in the Hatha Yoga classes, but the RAP program will differ from this traditional yoga practice in a number of ways: (1) the classes will be set to rock/heavy metal music; (2) meditation will not be incorporated; (3) yoga terms will not be used to describe the body positions (rather, positions will be cued in plain descriptive English terms); (4) the culminating activity for the class will be called a 'cool down' (rather than the savasana exercise typically used in yoga practice).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The control group will comprise a program akin to Hatha yoga with chair modifications available to all Veterans who choose/need to use them.
Study: NCT06146842

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: Each subject will receive allocated dose of bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: Each subject will receive allocated dose of bupivacaine
Study: NCT05315635

Intervention type: OTHER
Intervention: Questionnaire
Description: Patients treated for substance use disorders and patients treated for eating disorders will have to complete self-questionnaires and a clinical psychiatric (MINI) at the inclusion.~Patients suffering from substance use disorder will be assessed 3 weeks after inclusion.~Questionnaires are :~* Modified Yale Food Addiction (mYFAS 2.0) and Impulsive Behavior Scale (UPPS-P)~* Trait Meta-Mood Scale (TMMS), Hospital Anxiety and Depression Scale (HADs), Emotional Appetite Questionnaire (EMAQ), Perceived Stress Scale (PSS-10), Multidimensional Assessment of Interoceptive Awareness (MAIA) and Five Facet Mindfulness Questionnaire (FFMQ)~* Mini International Neuropsychiatric Interview (MINI), Eating Disorder Examination-Questionnaire (EDE-Q), Rosenberg's Self Esteem (RSE) and Ruminative Response Scale for Eating disorders (RRS-ED)~* Pittsburgh Sleep Quality Index (PSQI) and Montreal Cognitive Assessment (MoCA)
Study: NCT05755022

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Maxillary Segment Repositioning
Description: * Le-Fort I osteotomy will be made using the cutting guide.~* Mobilization of the maxilla will be done.~* The osteotomized segment will be positioned using the positioning guide that will be fabricated utilizing the reverse engineering technology using 3D photogrammetry technique.~* While the guide in place, the plates will be fixed into their intended position.~* After fixation of the plates, the guide will be removed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Maxillary Segment Repositioning
Description: * Le-Fort I osteotomy will be made using the cutting guide.~* Mobilization of the maxilla will be done.~* The osteotomized segment will be positioned using the positioning guide that will be fabricated utilizing the reverse engineering technology using the commercial scanners.~* While the guide in place, the plates will be fixed into their intended position.~* After fixation of the plates, the guide will be removed.
Study: NCT05870462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide Pen Injector
Description: * 0.25 mg/week (non-therapeutic dose) during Weeks 1-4~* 0.50 mg/week during Weeks 5-8~* 1.0 mg/week during Weeks 9-24~Participants experiencing side effects (e.g. nausea, stomach pain, constipation, diarrhea, vomiting) at the maximum dose (1.0 mg/week) may be down-titrated to 0.50 mg/week.~Participants who had been receiving a dipeptidyl peptidase 4 (DPP-4) inhibitor (sitagliptin, saxagliptin, linagliptin, alogliptin) will stop taking their DPP-4 inhibitor upon randomization to this arm.
Study: NCT05211258

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: a novel portable upper gastrointestinal endoscopy system
Description: Patients arrived at the hospital in the morning after an overnight fast (\>6 hours). The patients took oral dyclonine glue 15 mins before their examination. The doctors prepared the portable endoscopy system so that it was in working status and the disposable sheathed system was placed on the endoscope optical probe.
Study: NCT05681338

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the medium intensity coughing technique
Description: The medium intensity coughing technique: Immediately before the subcutaneous LMWH injection was given, patients were asked to cough twice at a medium level. After that, they were asked to cough ten seconds later for a second time at the same level, and while they were coughing for the second time, the needle was inserted into the tissue.
Study: NCT06192290

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based transitional Cardiac Telerehabilitation
Description: This comprehensive series is divided into 16 parts, each addressing crucial aspects of open-heart surgery recovery. Part 1 introduces open-heart surgery, heart disease symptoms, and preoperative preparations for elderly patients. Part 2 delves into cardiac rehabilitation, defining objectives and detailing recovery stages. Part 3 covers care for surgical incisions and infection signs. Part 4 explores sleep and rest, while Part 5 guides patients on a healthy post-surgery diet. Part 6 focuses on nursing interventions for dyspnea, and Part 7 addresses post-surgery cough. Part 8 discusses nursing interventions for thrombosis prevention
Study: NCT06104007

Intervention type: DEVICE
Intervention: Genoss® DCB
Description: This study includes patients with coronary in-stent restenosis (ISR) who have undergone percutaneous coronary intervention (PCI) according to standard treatment protocols using the Genoss® DCB and have agreed to participate in the clinical research. The decision on which drug-coated balloon (DCB) to use during PCI is entirely based on the patient's condition and the characteristics of the coronary lesions identified through angiography. Thus, it's not possible to determine in advance to use the Genoss® DCB before the procedure, nor can the number of drug-coated balloon catheters to be used during the procedure be known or decided upon beforehand.
Study: NCT05324592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9MW0813
Description: The active ingredient of 9MW0813 injection is recombinant human vascular endothelial growth factor receptor-antibody fusion protein.~One dose(2mg) of the drug will be injected intravitreously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: Aflibercept (trade name: Eylea®/EYLEA®) is an anti-VEGF drug developed by Regeneron/Bayer. It is a fusion protein of human VEGFR1 and VEGFR2 extracellular domains and human immunoglobulin Fc segment genes.~One dose(2mg) of the drug will be injected intravitreously.
Study: NCT05346276

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-DOTA-hLAG-3 PET/CT
Description: Each participant receives a single intravenous injection of 68Ga-DOTA-hLAG-3, and undergo PET/CT imaging within the specified time.
Study: NCT04801485

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: D-chiro inositol
Description: Active group receives inositol 1 gram per day as well as health guidance about diet and exercise. From recruitment until OGTT.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (similar appearance but not containing myo-inositol) 1 gram per day before meals. Similar health guidance about diet and exercise. From recruitment until OGTT.
Study: NCT04074083

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: electronic IMCI
Description: Participants will be trained to use an electronic version of the Integrated Management of Childhood Illness (IMCI) guidelines

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: paper IMCI
Description: Participants will be trained to use routine paper version of Integrated Management of Childhood Illness (IMCI) guidelines
Study: NCT06398002

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dialysate calcium 1.50 mmol/L
Description: Increased dialysate calcium of 1.50 mmol/L (as compared to standard dialysate calcium of 1.25 mmol/L)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dialysate calcium 1.50 mmol/L
Description: Increased dialysate calcium of 1.50 mmol/L (as compared to standard dialysate calcium of 1.25 mmol/L)
Study: NCT05193968

Intervention type: OTHER
Group type: OTHER
Intervention: Sympathoexcitatory stressors
Description: Muscle sympathetic nerve activity will be measured continuously at baseline and in response to sympathoexcitatory stressors, including a Valsalva maneuver, isometric handgrip exercise, a cold pressor test, and stepped hypercapnia.

Intervention type: DRUG
Group type: OTHER
Intervention: Sodium Nitroprusside
Description: Sodium nitroprusside, used to test endothelium-independent vasodilation, will be infused through a brachial artery catheter at 0.25, 0.5, 1.0 and 2.0 ug/100ml tissue/min.

Intervention type: DRUG
Group type: OTHER
Intervention: Acetylcholine
Description: Acetylcholine, used to test endothelium-dependent vasodilation, will be infused through a brachial artery catheter at 1.0, 2.0, 4.0, and 8.0 μg/100ml tissue/min

Intervention type: DRUG
Group type: OTHER
Intervention: Terbutaline
Description: Terbutaline, a β2-Adrenergic selective agonist, will be infused through a brachial artery catheter at 0.1, 0.5, 1.0, and 2.0 μg/100ml tissue/min.

Intervention type: DRUG
Group type: OTHER
Intervention: Norepinephrine
Description: Norepinephrine, an α-adrenergic vasoconstricting agent, will be infused through a brachial artery catheter at 1.0, 2.0, 4.0, and 8.0 ng/100ml tissue/min
Study: NCT05689489

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Puzzle Method
Description: While preparing the puzzle to be used in the study, the puzzle preparation program will be used (Crossword Puzzle Maker). Students in the initiative group will be asked to solve a total of 6 puzzles, one puzzle each week. The answers to the prepared puzzles will cover the theoretical course topics of psychiatric nursing. In the puzzles, students will be expected to place their answers in the specified rows and columns. Students will be asked to solve puzzles individually. In addition, the answer to each puzzle will be found on the reverse on the back page. Students will be reminded that there is no time limit for solving the puzzles. Researchers will guide students while students solve puzzles.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ongoing Education
Description: Students in the control group will only take the theoretical course of psychiatric nursing.
Study: NCT04616170

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hip extension
Description: Hips extended at the time of vaginal delivery

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Hips positioned in the usual care position per provider preference at the time of vaginal delivery
Study: NCT05034809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin 20 MG
Description: Melatonin, also known as N-acetyl-5-methoxytryptamine will be the main intervention given to participating patients of this study. This study will use a dose of 20mg/day using the commercially available 5mg/tablet20-21. If a patient cannot be tolerate swallowing the whole tablet, it will be crushed and mixed with milk. According to the study done by Shah et al. there was no degradation in the active component of melatonin when mixed with milk or food as a medium for drug delivery.
Study: NCT05196750

Intervention type: OTHER
Intervention: Behavioural questionnaires and assessments on mother and child
Description: Questionnaires include, but not limited to, State Trait Anxiety Inventory, Beck Depression Inventory, LYNDON Maternal Health and Well Being, Facial Imitation Task, Deferred Imitation, Habituation, Relational Binding, Behavioural Observation, Mirror Self Recognition, Standardized Assessment and Experimental Task, Snack and Sticker Delay, Implicit Attitude Test

Intervention type: OTHER
Intervention: Behavioural questionnaires and assessments on mother and child
Description: Questionnaires include, but not limited to, State Trait Anxiety Inventory, Beck Depression Inventory, LYNDON Maternal Health and Well Being, Facial Imitation Task, Deferred Imitation, Habituation, Relational Binding, Behavioural Observation, Mirror Self Recognition, Standardized Assessment and Experimental Task, Snack and Sticker Delay, Implicit Attitude Test
Study: NCT04856150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Q-1802
Description: Q-1802 will be administered intravenously.
Study: NCT05133791

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Annexin A5
Description: Annexin A5 coupled to IRDye800CW as a potential treatment for RVO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Annexin A5
Description: Annexin A5 coupled to IRDye800CW as a potential treatment for RVO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Annexin A5
Description: Annexin A5 coupled to IRDye800CW as a potential treatment for RVO
Study: NCT05157906

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education based
Description: The interventional materials will be provided digitally for 12 weeks, with the monthly theme featured from the educational Grow Happy book and related tips and videos that will be released weekly.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: At enrollment, subject will be provided with the Mother and Child booklet, which is the Indonesian standard of care for parenting guidance.
Study: NCT06456983

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: maintenance electroconvulsive therapy (mECT)
Description: see Arms
Study: NCT06345365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoxantrone liposome, Ara-Cytarabine and azacitidine
Description: Mitoxantrone hydrochloride liposome 24 mg/m2, IV every 4 weeks, day 1; Ara-Cytarabine 100 mg/m2, IV every 12 h, days 1-7; Azacitidine 100 mg, subcutaneous, once daily, days 1 to 7

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daunorubicin,Ara-Cytarabine, azacitidine
Description: Daunorubicin 60 mg/m2, intravenously, once daily, days 1 to 3; Ara-Cytarabine 100 mg/m2, IV drip, every 12h, days 1 to 7; Azacitidine 100 mg, subcutaneous, once daily, days 1 to 7;
Study: NCT06168786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Description: Fruquintinib:5mg ,qd,po, d1-d14, q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab
Description: Cadonilimab:10mg/kg, ivgtt, d1, q3w

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: SBRT:8-10Gy×5F，qod， in 10 days
Study: NCT05591586

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Web based educational modules
Description: This strategy will consist of 6 web-based modules, clinic-specific interpreter access information, and 4 booster modules, all delivered via the internet. The online modules will cover 6 topics: 1) the importance and fundamentals of good communication; 2) the importance of professional interpreter use and disparities for LEP populations; 3) how to use an interpreter effectively; 4) what to do when the encounter is not going well; and 5) special challenges and 6) solutions related to remote interpreter use. Modules will be interactive, with tailoring to the learner, and each will be \<15 minutes long. All modules will be available at once, but assigned providers will be prompted to view a new one each week. Every month for months 3-6 after randomization, a booster module will be released. The brief (\<10 min) boosters will review crucial points from initial modules and feature video vignettes. Providers will be reminded to view these weekly until they are complete.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mobile video interpreting (mVI) access
Description: This strategy will involve giving assigned providers access to mobile video interpreting (mVI) on a personal device, installation and support as needed, a tip sheet, and an extra charger, optional shock-resistant case, disposable antimicrobial sleeves, and a positioning stand to support use of their personal device for clinical care. mVI-assigned providers can opt for a study-issued smartphone in lieu of using their own. Access to mVI is achieved by downloading the application from the relevant location (e.g., Apple App Store), then entering an access code that links to a billing account. The study staff would then demonstrate use and answer questions. Technical support will be offered in-person following randomization; we will then email mVI-assigned providers weekly for the first month, then monthly, to offer additional support. A tip-sheet will be sent via email during the first week of the study that will include mVI instructions and best-practices.
Study: NCT05347381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexol and Dexamethasone
Description: Selinesol 20mg/tablet 60mg po qw first week, second week, biw third week, namely d1, d8, d15, d18.~Dexamethasone 0.75mg/tablet 1.5mg po bid d1-21;
Study: NCT04227353

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HEAL ABC
Description: Participants will be assigned their first booklet based on the one they perceive to be the easiest for setting an incremental goal and achieving it. After the participant achieves successful behaviour change, he or she can move more confidently to the next booklet. Support will be provided every two weeks over the phone for 12 weeks. During the follow-up period, participants will use the follow-up booklet which helps them to continue with changes they have made and encourage them to set new goals.
Study: NCT05765630

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BLOOD SAMPLES
Description: BLOOD SAMPLES

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BLOOD SAMPLES
Description: BLOOD SAMPLES

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BLOOD SAMPLES
Description: BLOOD SAMPLES

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BLOOD SAMPLES
Description: BLOOD SAMPLES

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BLOOD SAMPLES
Description: BLOOD SAMPLES
Study: NCT05940155

Intervention type: DIAGNOSTIC_TEST
Intervention: RT PCR test of COVID 19
Description: diagnostic test by naso-pharyngel swab to confirm the diagnosis of covid-19 at moderate and severe cases.

Intervention type: DIAGNOSTIC_TEST
Intervention: RT PCR test of COVID 19
Description: diagnostic test by naso-pharyngel swab to confirm the diagnosis of covid-19 at moderate and severe cases.
Study: NCT06162130

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Eccentric quadriceps exercises
Description: The activation of the vastus medialis, vastus lateralis, and rectus femoris muscles will be measured using surface electromyography (sEMG) during four distinct quadriceps eccentric exercises: Reverse Nordic, Pistol squat, Suspension-based Bulgarian split squat, and Bulgarian split squat. Participants will be instructed to perform three successful repetitions for each exercise. A 30-second break will be provided between each repetition, and there will be a minimum of 10 minutes of rest between each of the four exercises. Due to the belief that fatigue could impact exercise performance, the modified Borg scale will be used to ensure that fatigue does not occur before each exercise. Exercise recording will commence when scores reported using the modified Borg scale are 1 or lower.
Study: NCT05558423

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time Restricted Eating
Description: Participants are asked to follow a Time Restricted Eating regimen with eating window of ≤10 hours.
Study: NCT03813433

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Revascularization
Description: a procedure used to regenerate pulp dentin complex that restores the functional properties of this immature anterior teeth, prevent and resolves apical periodontitis

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Revascularization
Description: a procedure used to regenerate pulp dentin complex that restores the functional properties of this immature anterior teeth, prevent and resolves apical periodontitis
Study: NCT05137834

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Post-surgical exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Post-surgical exercise